InMed Pharmaceuticals (INM) Competitors $2.72 +0.05 (+1.87%) Closing price 04/17/2025 03:56 PM EasternExtended Trading$2.65 -0.07 (-2.57%) As of 04/17/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. AFMD, MEIP, IMNN, CLDI, ORGS, SLGL, ABVC, TXMD, MRKR, and IBIOShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Affimed (AFMD), MEI Pharma (MEIP), Imunon (IMNN), Calidi Biotherapeutics (CLDI), Orgenesis (ORGS), Sol-Gel Technologies (SLGL), ABVC BioPharma (ABVC), TherapeuticsMD (TXMD), Marker Therapeutics (MRKR), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Affimed MEI Pharma Imunon Calidi Biotherapeutics Orgenesis Sol-Gel Technologies ABVC BioPharma TherapeuticsMD Marker Therapeutics iBio Affimed (NASDAQ:AFMD) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends. Is AFMD or INM more profitable? InMed Pharmaceuticals has a net margin of -163.75% compared to Affimed's net margin of -7,836.26%. InMed Pharmaceuticals' return on equity of -90.74% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Affimed-7,836.26% -193.84% -107.24% InMed Pharmaceuticals -163.75%-90.74%-71.70% Does the MarketBeat Community favor AFMD or INM? Affimed received 431 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 69.90% of users gave Affimed an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAffimedOutperform Votes43969.90% Underperform Votes18930.10% InMed PharmaceuticalsOutperform Votes847.06% Underperform Votes952.94% Which has more volatility and risk, AFMD or INM? Affimed has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Do analysts recommend AFMD or INM? Affimed currently has a consensus target price of $13.50, indicating a potential upside of 1,740.49%. Given Affimed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Affimed is more favorable than InMed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80InMed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation & earnings, AFMD or INM? InMed Pharmaceuticals has higher revenue and earnings than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAffimed$877K13.47-$114.66MN/AN/AInMed Pharmaceuticals$4.83M0.68-$7.68M-$13.75-0.20 Do institutionals & insiders have more ownership in AFMD or INM? 30.8% of Affimed shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 3.8% of Affimed shares are held by company insiders. Comparatively, 1.9% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to AFMD or INM? In the previous week, Affimed and Affimed both had 1 articles in the media. Affimed's average media sentiment score of 0.00 beat InMed Pharmaceuticals' score of -1.00 indicating that Affimed is being referred to more favorably in the media. Company Overall Sentiment Affimed Neutral InMed Pharmaceuticals Negative SummaryAffimed beats InMed Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.28M$6.46B$5.32B$7.35BDividend YieldN/A3.21%5.47%4.34%P/E Ratio-0.206.9521.9417.82Price / Sales0.68231.01380.9597.73Price / CashN/A65.6738.3134.64Price / Book0.535.936.453.98Net Income-$7.68M$143.22M$3.22B$247.81M7 Day Performance-0.73%4.28%5.85%3.19%1 Month Performance-3.20%-13.11%-9.58%-7.70%1 Year Performance-53.11%-8.51%11.85%1.49% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals0.3145 of 5 stars$2.72+1.9%N/A-53.0%$3.28M$4.83M-0.2010Short Interest ↑AFMDAffimed3.5104 of 5 stars$0.79+27.2%$13.50+1,606.9%-85.8%$12.73M$877,000.000.00200Analyst ForecastNews CoverageGap UpMEIPMEI Pharma2.2306 of 5 stars$1.91+2.1%N/A-39.4%$12.73M$65.30M-0.33100Analyst ForecastShort Interest ↓Gap DownIMNNImunon1.6264 of 5 stars$0.87+2.4%$21.50+2,371.3%-23.9%$12.72M$500,000.00-0.4630Short Interest ↑Negative NewsCLDICalidi Biotherapeutics2.2833 of 5 stars$0.43-1.4%$15.00+3,357.0%N/A$12.35M$50,000.000.0038News CoverageGap UpORGSOrgenesisN/A$2.50+26.9%N/AN/A$12.00M$662,000.000.00150Upcoming EarningsGap DownSLGLSol-Gel Technologies1.9754 of 5 stars$0.43-0.4%$5.00+1,067.1%-40.8%$11.93M$11.71M-1.2650News CoverageGap UpABVCABVC BioPharma0.8341 of 5 stars$0.92+0.6%N/A-13.6%$11.93M$509,788.00-1.0730Earnings ReportGap UpTXMDTherapeuticsMD1.0261 of 5 stars$1.03+4.1%N/A-45.7%$11.92M$1.76M0.00420Analyst ForecastNews CoverageMRKRMarker Therapeutics3.2566 of 5 stars$1.10+6.8%$13.17+1,097.0%-72.2%$11.78M$6.59M-0.9260News CoverageIBIOiBio1.081 of 5 stars$1.18-1.7%$4.30+264.4%-48.0%$11.65M$375,000.000.00100 Related Companies and Tools Related Companies AFMD Alternatives MEIP Alternatives IMNN Alternatives CLDI Alternatives ORGS Alternatives SLGL Alternatives ABVC Alternatives TXMD Alternatives MRKR Alternatives IBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
